The global liquid biopsy market, valued at USD 8.20 billion in 2025, is projected to reach USD 9.49 billion in 2026 and USD 33.45 billion by 2035, representing a CAGR of 15.0% during the forecast period 2026 to 2035. Liquid biopsy solutions offer a minimally invasive and accessible method for early cancer detection and patient monitoring. This is primarily because of their superior ability to perform high-throughput multi-gene profiling, the ongoing reduction in sequencing costs, and its high se...

The global systemic lupus erythematosus market size, valued at USD 2,669 million in 2025, is projected to reach USD 2,471 million in 2026 and USD 6,547 million by 2035, representing a CAGR of 11.4% during the forecast period 2026 to 2035. Based on the route of administration, intravenous route captures the largest share (close to 70%) of the current market; this trend is unlikely to change in the future. Amongst the types of therapy, combination therapies capture the most (nearly 95%) of the cur...

The global live cell encapsulation market, valued at USD 613 million in 2025, is projected to reach USD 642 million in 2026 and USD 1,787 million by 2035, representing a CAGR of 12.1% during the forecast period 2026 to 2035. In terms of therapeutic area, metabolic disorders are likely to hold the highest share (over 40%) of the future market share. Based on the type of payment, upfront payments capture the largest share (over 85%) of the current market. In terms of geographical regions, North Am...

The global single use downstream bioprocessing market, valued at USD 3.78 billion in 2025, is projected to reach USD 4.21 billion in 2026 and USD 12.15 billion by 2035, with a CAGR of 12.5% during the forecast period 2026 to 2035. With respect to the scale of operation, commercial scale currently holds around 80% of the market share. This single use downstream bioprocessing market trends is driven by the transition of drug candidates from clinical to commercial stages, which demands high-volume...

The global next generation immune checkpoint inhibitors market, valued at USD 15.4 billion in 2025, is projected to reach USD 17.5 billion in 2026 and USD 20.9 billion by 2035. Based on type of molecule, biologics are likely to hold the highest market share (close to 97%), in the current year. Based on geographical regions, North America is projected to capture the majority share of the market, in 2035. In terms of sales forecast for therapies, Darzalex will hold the highest market share by secu...

The global AI-Powered claim denial management market is expected to rise from USD 1.35 billion in 2026 and is projected to reach USD 15.0 billion by 2040, growing at a CAGR of 18.8% over the forecast period 2026 to 2040, driven by rising claim denials and payer-policy complexity. Based on geography, North America captures 47.0% market share in 2026, whereas Asia-Pacific registers a 22.6% CAGR through 2040, driven by public claims digitization.

The global ready to use pharmaceutical packaging market, valued at USD 13.7 billion in 2025, is projected to reach USD 15.0 billion in 2026 and USD 39.9 billion by 2035, with a CAGR of 11.5% during the forecast period 2026 to 2035. In terms of type of pre-sterilized / ready to use pharmaceutical packaging systems, closures secure 65% of the overall revenue share. In January 2026, Becton Dickinson and Company (BD) announced USD 110 million investment to expand its ready to use prefilled syringe p...

The global dual chamber devices market, valued at USD 5.81 billion in 2025, is likely to reach USD 6.25 billion in 2026 and USD 17.56 billion by 2040, representing a CAGR of 7.7% during the forecast period. Based on the material of fabrication, glass is likely to capture more than 90% of the overall dual chamber devices for prefilled syringes market share in 2026. This is because of the inherently sterile and inert nature of glass with great barrier properties. Based on volume of container, >1ml...

The global biopharmaceutical contract manufacturing market, valued at USD 28.0 billion in 2025, is projected to reach USD 31.0 billion in 2026 and USD 63.9 billion by 2035, with a CAGR of 8.3% during the forecast period 2026 to 2035. In terms of type of expression system used, mammalian expression systems currently hold around 80% of the market share, due to their superior ability to produce complex proteins by mimicking human biology. In terms of scale of operation, commercial scale segment cap...

The global antibody contract manufacturing market, valued at USD 19.0 billion in 2025, is projected to reach USD 21.2 billion in 2026 and USD 49.1 billion by 2035, with a CAGR of 9.7% during the forecast period 2026 to 2035. In terms of the type of antibody manufactured, monoclonal antibodies currently capture (95%) of the market share due to the fact that monoclonal antibodies are highly specific, consistent in structure, and are usually produced in large quantities. Based on the therapeutic a...

The global radiopharmaceutical last-mile logistics market reached USD 1.20 billion in 2026 and is projected to reach USD 5.65 billion by 2040, growing at a CAGR of 11.7% over the forecast period 2026 to 2040, driven by time-critical nuclear medicine delivery growth. Based on Radiopharmaceutical Type, PET radiopharmaceuticals capture 33.0% market share in 2026, whereas theranostic radiopharmaceuticals register a 17.4% CAGR through 2040, driven by paired diagnostic and therapeutic oncology pathway...

The global medical device contract manufacturing market size, valued at USD 92.6 billion in 2025, is projected to reach USD 99.8 billion in 2026 and USD 181.4 billion by 2035, with a CAGR of 6.9% during the forecast period 2026 to 2035. This market is growing steadily, driven by continuous technological advancements, leading to the development of complex and innovative medical devices. This has prompted the medical device companies to seek specialized services from medical device contract manufa...

The cloud computing market, valued at USD 818 billion in 2025, is projected to grow to USD 950 billion in 2026 and USD 5,608 billion by 2040, representing a CAGR of 13.52% during the forecast period. The high demand for flexible and cost-effective IT solutions has led to a shift from conventional on-premises systems to cloud-based services, enhancing efficiency and minimizing operational costs. This shift reduces the need for extensive physical hardware and maintenance, allowing businesses t...

The global mRNA vaccine and therapeutics market, valued at USD 9 million in 2026, is projected to reach USD 17,036 million by 2035, representing a high CAGR during the forecast period 2026 to 2035. In terms of geographical regions, North America holds 75% of the market share due to the growing research, favorable regulatory guidelines for approval of mRNA vaccines and therapeutics, and a strong presence of key mRNA developers. In January 2026, Moderna secured a strategic capital commitment of US...

The global photodynamic therapy market, valued at USD 672 million in 2025, is projected to reach USD 749 million in 2026 and USD 1,532 million by 2035, representing a CAGR of 8.3% during the forecast period 2026 to 2035. In terms of target indication, actinic keratosis holds the highest share (over 35%) of the market. According to American Cancer Society, there were 104,960 new cases of skin cancer reported in 2025 in the US alone, with high recurrence rates. For instance, basal cell carcinoma...

The global virtual ward market is expected to rise from USD 3.10 billion in 2026 to reach USD 17.80 billion by 2040, growing at a CAGR of 13.3% over the forecast period 2026 to 2040, driven by hospital capacity pressure, remote monitoring maturity, and payer support for hospital-at-home models. Based on geography, North America captures 41.4% market share in 2026, whereas Asia-Pacific registers a 15.6% CAGR through 2040, driven by digitalization and hospital-capacity localization. Integration bu...

The global non-viral transfection reagents market, valued at USD 0.79 billion in 2025, is projected to reach USD 0.89 billion in 2026 and USD 2.01 billion by 2035, representing a CAGR of 9.5% during the forecast period 2026 to 2035. In October 2025, MaxCyte signed a platform licensing agreement with Moonlight Bio, granting non-exclusive research, clinical, and commercial rights to Moonlight Bio’s Flow Electroporation technology and ExPERT platform for scalable development and manufacturing of...

The global connected drug delivery devices market, valued at USD 4.8 billion in 2025, is projected to reach USD 5.3 billion in 2026 and USD 12.7 billion by 2035, representing a CAGR of 10.2% during the forecast period 2026 to 2035. Research indicates that about 66% of people in the US receive at least one prescription, but nearly 50% of them do not take their medicines as physicians direct. As a result, several players are actively involved in the development of innovative drug delivery devices...

The global rapid microbiology testing solutions market, valued at USD 560 million in 2025, is projected to reach USD 603 million in 2026 and USD 1,463 million by 2035, representing a 10.3% CAGR during the forecast period 2026 to 2035. In 2035, North America is likely to have high rapid microbiology testing solutions market size, capturing around 40% of the overall market share. This dominance is attributed to the presence of a well-established pharmaceutical manufacturing base, early adoption of...

The biologics safety testing market size, valued at USD 4.9 billion in 2025, is projected to reach USD 5.3 billion in 2026 and USD 9.4 billion by 2035, representing a CAGR of 6.6% during the forecast period 2026 to 2035. In terms of end-user, the pharmaceutical and biotechnology companies segment accounts for around 50% of the overall revenue share. North America is holding close to 40% of the market share due to its strong public and private investments, supportive regulations, and significant...